Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Receivables (2019 - 2026)

Biodesix filings provide 8 years of Receivables readings, the most recent being $9.5 million for Q1 2026.

  • On a quarterly basis, Receivables rose 24.36% to $9.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.5 million, a 24.36% increase, with the full-year FY2025 number at $9.0 million, up 5.03% from a year prior.
  • Receivables hit $9.5 million in Q1 2026 for Biodesix, up from $9.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.7 million in Q3 2025 to a low of $3.8 million in Q1 2022.
  • Median Receivables over the past 5 years was $7.6 million (2025), compared with a mean of $7.3 million.
  • Biggest five-year swings in Receivables: plummeted 79.45% in 2022 and later skyrocketed 145.88% in 2024.
  • Biodesix's Receivables stood at $5.1 million in 2022, then skyrocketed by 51.61% to $7.7 million in 2023, then increased by 12.03% to $8.6 million in 2024, then rose by 5.03% to $9.0 million in 2025, then grew by 5.14% to $9.5 million in 2026.
  • The last three reported values for Receivables were $9.5 million (Q1 2026), $9.0 million (Q4 2025), and $12.7 million (Q3 2025) per Business Quant data.